论文部分内容阅读
目的探讨肝动脉门静脉输注自体ＬＡＫ细胞在肝癌肝脏灌注化疗中的临床价值。方法病理证实的原发性肝癌患者９２例，１４例肝动脉门静脉输注自体ＬＡＫ细胞及化疗药物，７８例肝动脉门静脉输注化疗药物作为对照。结果自体ＬＡＫ细胞加化疗组ＣＲ６例，ＰＲ６例，有效率８５．７％；对照组ＣＲ１７例，ＰＲ２８例，有效率５７．７％；两组间疗效有显著性差异（Ｐ＜０．０５）。结论肝动脉门静脉输注自体ＬＡＫ细胞可以提高肝癌肝脏灌注化疗的效果，经埋植式给药装置肝动脉门静脉输注自体ＬＡＫ细胞及化疗药物治疗中晚期肝癌的研究具有实际临床意义。
Objective To investigate the clinical value of hepatic arterial portal vein infusion of autologous LAK cells in liver infusion chemotherapy for liver cancer. Methods Pathologically confirmed 92 cases of primary liver cancer patients, 14 cases of autologous portal vein infusion of autologous LAK cells and chemotherapy drugs, and 78 cases of hepatic arterial portal vein infusion of chemotherapy drugs as controls. Results Autologous LAK cells plus chemotherapy group CR6 cases, PR6 cases, an effective rate of 85.7%; control group CR17 cases, PR28 cases, effective rate 57.7%; the effect between the two groups was significantly different (P<0.05) . Conclusion Autologous LAK cells transfused by hepatic arterial portal vein can improve the effect of hepatic hepatic infusion chemotherapy. The study of hepatic arterial portal vein infusion of autologous LAK cells and chemotherapeutic drugs for the treatment of advanced hepatocellular carcinoma by implanted device has practical significance.